CADTH Health Technology Review

Delayed Tuberculin Skin Testing
Table of Contents

Abbreviations .................................................................................................................. 5
Key Messages .................................................................................................................. 6
Context and Policy Issues .............................................................................................. 6
Research Questions ........................................................................................................ 7
Methods .......................................................................................................................... 8
  Literature Search Methods............................................................................................. 8
  Selection Criteria and Methods ..................................................................................... 8
  Exclusion Criteria........................................................................................................... 9
  Critical Appraisal of Individual Studies ....................................................................... 9
Summary of Evidence .................................................................................................... 9
  Quantity of Research Available..................................................................................... 9
  Summary of Study Characteristics................................................................................ 9
  Summary of Critical Appraisal....................................................................................... 10
  Summary of Findings..................................................................................................... 11
Limitations ....................................................................................................................... 12
Conclusions and Implications for Decision- or Policy-Making ...................................... 12
References ...................................................................................................................... 14
Appendix 1: Selection of Included Studies ..................................................................... 15
Appendix 2: Characteristics of Included Publications .................................................... 16
Appendix 3: Critical Appraisal of Included Publications ................................................ 18
Appendix 4: Main Study Findings ................................................................................... 19
Appendix 5: References of Potential Interest .................................................................. 20
List of Tables

Table 1: Selection Criteria ........................................................................................................... 8
Table 2: Characteristics of Included Guideline ........................................................................... 16
Table 3: Strengths and Limitations of Guideline Using AGREE II ................................. 18
Table 4: Summary of Recommendations in Included Guideline ........................................... 19

List of Figures

Figure 1: Selection of Included Studies ...................................................................................... 15
Abbreviations

**GRADE**  Grading of Recommendations, Assessment, Development and Evaluations
**IGRA**  interferon gamma release assay
**TB**  tuberculosis
**TST**  tuberculin skin testing
Key Messages

- With delayed tuberculin skin testing (TST) a single TST is performed to screen for tuberculosis (TB) infection 8 weeks after exposure to a known case of TB.
- The clinical utility (i.e., clinical benefits and harms of testing) of delayed TST for identifying TB among close contacts with no known risks compared to testing immediately after and at 8 weeks after TB exposure is not known (no evidence was found).
- It is not known if delayed TST is a cost-effective approach for identifying TB among close contacts with no known risks compared to testing immediately after and at 8 weeks after TB exposure (no evidence was found).
- One evidence-based guideline developed in Canada does not provide specific recommendations regarding delayed TST in close contacts with no known risks of TB. However, the guideline authors discuss that a single TST at 8 weeks after TB exposure could be a practical option for medium-priority contacts (i.e., those with a lower risk to develop active disease). For high-priority contacts (i.e., those with the most exposure and highest risk to develop active disease), the authors propose testing immediately after exposure and a repeat test 8 weeks later.

Context and Policy Issues

Tuberculosis (TB) is a communicable disease caused by the bacillus *Mycobacterium tuberculosis*. It is 1 of the most common causes of death worldwide. Globally, WHO estimated that about 10 million individuals had active TB in 2019. In Canada, prevalence of TB is relatively low at around 4.6 to 5.1 people per 100,000 population. Indigenous Peoples and foreign-born Canadian residents experience a disproportionately higher burden of TB. For example, the incidence rate in the Inuit population is about 70 per 100,000 and that among foreign-born-Canadians is about 15 per 100,000 population.

Spread from person to person through droplet or aerosol form, TB primarily affects the lungs; however, it can affect virtually all systems in the human body. With the advancement of medical science in the field of antibiotics, TB is curable with a treatment regime of 6 months, which can also prevent disease transmission. Post TB sequelae, the spectrum of conditions and complications in TB survivors, can lead to long-term disability and affect quality of life. Early identification and treatment of TB is crucial in disease management as well as in prevention of additional transmission.

When a TB case is diagnosed, contact investigation is essential in identifying active or latent infections. In Canada, contact investigations are initiated when a notification about a new infection is received by the public health authorities. Ideally, contact tracing interviews are conducted within 3 days and screening of high-priority contacts are arranged within 7 days. This would ensure early detection of TB infection in the contacts and preventive treatment, as required, can be provided to infected individuals. The contacts are prioritized based on location, duration of exposure and settings. High-priority contacts are the individuals with most exposure, at highest risk of progression to active TB. They include household contacts (e.g., living in the same house as index patient), household-like contacts (e.g., congregate settings such as jail, homeless shelter, or caregivers of index patient), and contacts in health care procedures with high risk of aerosol occurrence. Medium-priority contacts include those with a lesser risk of progression to active disease but have regular and frequent contact with
Presence of a TB infection can be identified using screening tests such as the TST or interferon gamma release assay (IGRA). TST is also known as purified protein derivative test or Mantoux test. The basis of TST is cell-mediated immunity against tuberculin antigens. In individuals who are infected with TB, administration of the purified protein derivative evokes a delayed-hypersensitivity reaction within 48 to 72 hours. This would result in swelling and induration at the injection site. TST is administered as an intradermal injection in the inner part of the forearm. Size of the subsequently developed induration is measured 48 to 72 hours later. Generally, at least 5 mm of induration is considered positive in high-risk individuals (e.g., persons living with HIV, known recent contact to patient with active TB). TST has several advantages and disadvantages. TST can be performed by a health care worker with minimal training even in remote locations, is inexpensive, and the results are relatively easy to measure. However, the main disadvantage of TST is that the patient needs to return to the test site in order for the results to be measured 2 to 3 days later. There is also inter-reader variability in measuring the induration, false-positive results possible due to cross reaction to other antigens, and a risk of adverse events.

Either TST or IGRA are recommended as screening tests for identifying TB infection. TST is recommended for serial or repeated testing in the context of a contact screening. This would require the individual to visit the test site or clinic multiple times - to receive the test and then to read the result over the course of several weeks. One of the main challenges with repeat testing is the drop-out rate between the tests, resulting in incomplete assessment of the contact. Delayed TST is proposed as a solution to this issue. In delayed TST, a single TST is administered 8 weeks post-exposure, rather than a TST to be administered immediately and then a second after 8 weeks post-exposure.

The purpose of this report is to summarize the evidence regarding the clinical utility, cost-effectiveness, and evidence-based guidelines regarding delayed TST in close contacts who have no known risk factors to require immediate testing.

CADTH has conducted a larger Condition Level Review on TB. A condition level review is an assessment that incorporates all aspects of a condition, including prevention, detection, treatment, and management. For more information on CADTH’s Condition Level Review of TB, please visit the project page (https://www.cadth.ca/tuberculosis).

**Research Questions**

1. What is the clinical utility of tuberculin skin testing at 8 weeks post-exposure to tuberculosis versus testing immediately after and at 8 weeks post-exposure to tuberculosis?

2. What is the cost-effectiveness of tuberculin skin testing at 8 weeks post-exposure to tuberculosis versus testing immediately after exposure and at 8 weeks post-exposure to tuberculosis?
3. What are the evidence-based guidelines informing the use of tuberculin skin testing at 8 weeks post-exposure to tuberculosis versus testing immediately after and at 8 weeks post-exposure to tuberculosis?

Methods

Literature Search Methods
A limited literature search was conducted by an information specialist on key resources including MEDLINE, the Cochrane Database of Systematic Reviews, the International HTA Database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's Mesh (Medical Subject Headings), and keywords. The main search concepts were tuberculin skin testing, tuberculosis, and timing or delayed testing. Additional focused searches were also run on the concepts contact tracing or testing and tuberculosis, combined with CADTH-developed search filters to limit retrieval to guidelines; and on the concept tuberculin skin testing combined with CADTH-developed search filters to limit retrieval to health technology assessments, systematic reviews, meta-analyses, or indirect treatment comparisons. Where possible, retrieval was limited to the human population. The search was completed on August 2, 2022 and limited to English-language documents published since January 1, 2012.

Selection Criteria and Methods
One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population</td>
<td>Q1 to Q3: People of any age who are found to be close contacts of tuberculosis and have no known risk factors that require immediate testing</td>
</tr>
<tr>
<td>Intervention</td>
<td>Q1 to Q3: Tuberculin skin testing at 8 weeks post-exposure</td>
</tr>
</tbody>
</table>
| Comparator     | Q1 and Q2: Tuberculin skin testing immediately after and at 8 weeks post-exposure  
|                | Q3: NA                                                                      |
| Outcomes       | Q1: Clinical utility i.e., benefits (e.g., adherence to testing, patient satisfaction, etc.) and harms (missed diagnoses, missed opportunity for early treatment, activation of tuberculosis, etc.)  
|                | Q2: Cost-effectiveness (e.g., cost per quality-adjusted life-year gained)  
|                | Q3: Evidence-based recommendations describing best clinical practice(s)      |
| Study designs  | Health technology assessments, systematic reviews, randomized-controlled trials, non-randomized studies, economic evaluations, evidence-based guidelines |
Exclusion Criteria
Articles were excluded if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, or were published before 2012. Systematic reviews in which all relevant studies were captured in other more recent or more comprehensive systematic reviews were excluded. Primary studies retrieved by the search were excluded if they were captured in 1 or more included systematic reviews. Guidelines with unclear methodology were also excluded.

Critical Appraisal of Individual Studies
The included publications were critically appraised by 1 reviewer following the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument as a guide. Summary scores were not calculated for the included studies; rather, the strengths and limitations of each included publication were described narratively.

Summary of Evidence

Quantity of Research Available
A total of 462 citations were identified in the literature search. Following screening of titles and abstracts, 423 citations were excluded and 39 potentially relevant reports from the electronic search were retrieved for full-text review. Two potentially relevant publications were retrieved from the grey literature search for full-text review. Of these 41 potentially relevant articles, 39 publications were excluded for various reasons, and 1 evidence-based guideline (across 2 publications) met the inclusion criteria and was included in this report. Appendix 1 presents the PRISMA flow chart of the study selection.

Additional references of potential interest are provided in Appendix 5.

Summary of Study Characteristics
The evidence-based guideline included in the report was the Canadian Tuberculosis Standards (the Standards), 8th Edition. Two chapters of the Standards that were relevant to the current report were included. Additional details regarding the characteristics of included publications are provided in Appendix 2.

Study Design
The Standards guideline was developed by the Canadian Thoracic Society and the latest update was published in 2022. The Standards covered several aspects of TB such as epidemiology, prevention, diagnosis, and management. Each chapter was informed by literature searches conducted between March 2021 and July 2021. Recent studies and systematic reviews were prioritized while assessing the evidence base. Search strategies and inclusion criteria for the literature search were not reported. Although it was reported that the authors undertook risk of bias assessment of the identified evidence, no formal tools were used for this. The authors did not follow a formal Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to evaluate the quality of the evidence due to the high number of recommendations. Each recommendation was developed by panel authors using consensus and finalized by the committee chair. A pre-defined framework
was used to assign the strength of recommendation as well as the level of evidence. Recommendations were graded as strong (intervention should be followed) or conditional (intervention can be considered depending on the individual patient). Quality of evidence for each recommendation were assigned as good or poor depending on the type and volume of studies identified for each recommendation. Recommendation statements formulated based on consensus of expert opinion were reported as a good practice statement. Lastly, recommendations supported by federal, provincial, or territorial legislation were listed as regulations.

Country of Origin
The guideline was developed in Canada.

Patient Population
The target population of the guideline was all individuals who are at risk of TB or those confirmed to have latent or active TB. Relevant to the current report, the population was individuals who were close contacts of TB and have no known risk factors. They include high-priority (e.g., household contacts, contacts in congregate settings such as jails) and medium-priority (e.g., close friends, co-workers, classroom contacts).

The intended users for the Standards were public health professionals, clinical specialists (e.g., internists, infectious disease specialists), primary care providers, and decision-makers.

Interventions and Comparators
The Standards provided recommendations regarding a broad range of interventions relating to various aspects of prevention, diagnosis, and management of TB. TST in contacts after exposure to TB was the intervention relevant to the current report.

Outcomes
The guideline did not report the specific outcomes considered during development and which outcomes were eligible during selection of supporting evidence.

Summary of Critical Appraisal
The details of the methodology and development of the Standards guideline were described in a separate document. The overall objective of the guideline was described, along with the population to which the guideline is meant to apply. They included all individuals with confirmed or at risk of active or latent TB. However, the health questions related to each recommendation were not specifically listed. The guideline authors were mostly clinical specialists from across Canada. Stakeholders such as public health professionals and policy advisors were also involved. The views and preferences of the target population were not sought. The intended users of the guideline were clearly described and were appropriate. The guideline was externally reviewed by topic experts before publication. A plan for future updates was outlined.

Overall, the rigour of development of the guideline had some limitations. Authors of each chapter conducted literature searches for identifying evidence. The authors did not report any methods for systematic search for evidence such as research questions, search strategy, or selection criteria. Therefore, the reproducibility of the evidence was low. No formal tools were used to assess the risk of bias of included evidence. GRADE process was not followed. However, an established framework was used to grade the recommendations and the
level of evidence. Recommendation statements were formulated through consensus of authors. Factors such as risk-benefit profile, cost, and implement ability were considered in establishing the strength of recommendations.

The recommendation statements were specific and clearly identifiable. Since the scope of the guideline was large, different aspects of TB care (e.g., prevention, diagnosis, management, and public health concerns) were described in separate chapters. Only the chapters relevant to the current report were reviewed here.6,7 Regarding the intervention relevant to the current report, no formal recommendation statements were made in the guideline. A standard approach to the screening of high- and medium-priority contacts using TST was described. However, the link between these general statements and supporting evidence related to them was unclear.

Facilitators and barriers to the application of guideline were not described. Tools for implementing the guideline, as well as monitoring criteria were not described. It was unclear whether potential resource implications of the recommendations were considered. Thus, the practical applicability of the guideline was low. There was editorial independence while developing the guideline. Potential conflicts of interests of the authors were declared and addressed. The guideline was funded by the Public Health Agency of Canada and the Canadian Thoracic Society. The authors reported that there was no external funding.

Additional details regarding the strengths and limitations are provided in Appendix 3.

Summary of Findings
Clinical Utility of Delayed TST
No relevant evidence regarding the clinical utility of delayed TST at 8 weeks post-exposure to TB versus testing immediately after and at 8 weeks post-exposure to TB was identified; therefore, no summary can be provided.

Cost-Effectiveness of Delayed TST
No relevant evidence regarding the cost-effectiveness of delayed TST at 8 weeks post-exposure to TB versus testing immediately after and at 8 weeks post-exposure to TB was identified; therefore, no summary can be provided.

Guidelines Regarding the Use of Delayed TST
Appendix 4 presents the detailed recommendations and general statements relevant to the current report.

The Standards conditionally recommends TST in situations where a repeat testing might be necessary such as a contact investigation or to identify new TB infections in high-risk settings.6

No specific formal recommendation statements were made regarding delayed TST at 8 weeks post-exposure to TB.

However, a standard approach to screening and evaluation of contacts after exposure to TB was discussed.6 The authors stated that high-priority contacts should have repeated testing. Ideally, a TST is to be done immediately after exposure to TB, or as soon as the contacts of the known TB case are identified. A second TST is warranted at least 8 weeks after the
In case of medium-priority contacts, the standards suggest that, a single round of screening after 8 weeks from last exposure is the practical option. Considering factors such as loss to follow-up for repeat testing, and the likelihood of detecting conversions, the authors suggested that if an initial screening cannot be arranged within 4 weeks of exposure, a single screening after 8 weeks is more efficient. Low priority casual contacts are not routinely screened. If they are investigated, a single TST 8 weeks or more from last day of exposure is suggested.

It should be noted that since these suggestions were not formal recommendations, a strength of recommendation or level of evidence was not provided. The supporting evidence for these suggestions was unclear from the publication.

Limitations

No evidence regarding the clinical utility or cost-effectiveness of delayed TST compared to testing immediately after and at 8 weeks post-exposure to TB among close contacts with no known risk factors was identified. Only 1 evidence-based guideline was included in this report. There were no formal evidence-based recommendations for or against delayed TST at 8 weeks post-exposure compared to repeat testing in close contacts. The guideline also had methodological limitations as described in the previous section.

Conclusions and Implications for Decision- or Policy-Making

One evidence-based guideline by the Canadian Tuberculosis Standards was included in this report. No specific recommendation regarding delayed TST among close contacts with no known risk factors was provided in the guideline. General statements from the guideline suggested that a single test after 8 weeks from last contact to a TB case could be a practical approach in medium-priority contacts. In high-priority contacts such as household close contacts, repeat testing (i.e., TST as soon as contact is established, and a second test 8 weeks later), is the preferred strategy. However, these were not formal evidence-supported recommendations and therefore should be interpreted with caution. Additionally, the guideline had several methodological limitations. Whether the guideline authors conducted a systematic search for evidence was not reported in the publication. The practical applicability of the guideline was low due to limited details on implementation, resource considerations, and criteria for monitoring adherence.

No evidence regarding the clinical utility or cost-effectiveness of delayed TST compared to testing immediately after and at 8 weeks post-exposure to TB among close contacts with no known risk factors was identified.

Overall, due to a limited volume of evidence identified, and the methodological limitations of the Standards guideline, the evidence regarding delayed TST for close contacts of TB is limited and remains uncertain.
A previous CADTH report identified 14 guidelines regarding the identification of latent and active TB. Recommendations for selective TB identification strategies, testing for latent TB infection, and diagnosis of active TB were summarized in that report. CADTH has also published reports on screening for latent TB infections in specific groups, such as in occupational settings, in post-secondary institutions, in people with compromised immunity before biologic therapy, and in people with existing chronic conditions.
References


Appendix 1: Selection of Included Studies

Figure 1: Selection of Included Studies

462 citations identified from electronic literature search and screened

423 citations excluded

39 potentially relevant articles retrieved for scrutiny (full text, if available)

2 potentially relevant reports retrieved from other sources (grey literature, handsearch)

41 potentially relevant reports

39 reports excluded:
- irrelevant population (11)
- irrelevant intervention (14)
- irrelevant comparator (1)
- guidelines of unclear methodology (5)
- other (review articles, editorials) (8)

2 reports (on 1 evidence-based guideline) included in review
Appendix 2: Characteristics of Included Publications

Table 2: Characteristics of Included Guideline

<table>
<thead>
<tr>
<th>Intended users, target population</th>
<th>Intervention and practice considered</th>
<th>Major outcomes considered</th>
<th>Evidence collection, selection, and synthesis</th>
<th>Evidence quality assessment</th>
<th>Recommendations development and evaluation</th>
<th>Guideline validation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intended users:</strong> Public health professionals, clinicians (e.g., primary care provider, infectious disease specialists), and decision-makers</td>
<td>Prevention, screening, diagnosis, and management of TB Relevant to the current report: Delayed TST</td>
<td>NR</td>
<td>Authors conducted literature searches. Search strategy, inclusion criteria NR. A systematic review was not conducted. Authors conducted risk of bias of included studies and quality of assessment. However, no formal appraisal tools were used. GRADE process was not conducted.</td>
<td>Strength of recommendation was reflected as: • Strong: the intervention should be used in most situations. There is clarity on the benefit vs. harms of the intervention. Based on &quot;good&quot; evidence (see below) • Conditional: the intervention should be considering, depending on the benefit and harm in an individual. There is likely a benefit of the intervention, but the magnitude of benefit could be uncertain. Based on &quot;poor&quot; evidence (see below). • Good practice statement: These are based on consensus of expert opinion. Not evidence-based or limited evidence to support. • Regulation: Supported by federal, provincial, or territorial legislation. No strength of evidence assigned. Level of evidence: Good = For diagnostic methods, 1 or more high quality RCT, 1 or more published SR of observational studies, or 2 or more observational studies are available as evidence. Poor = For diagnostic methods, 1 or more SR that concluded that the evidence was not high quality, 2 or more observational studies with</td>
<td>Recommendations were developed by chapter authors by consensus of the panel. Strength of recommendation was assigned based on the level of evidence available.</td>
<td>The guideline documents were reviewed internally within the committee. The key recommendations were presented at a meeting and sought feedback from all authors. External reviewers (topic experts) as well as members of the CRGC reviewed the chapters before publishing.</td>
</tr>
<tr>
<td><strong>Target population:</strong> All individuals at risk of, or with confirmed active or latent TB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Canadian Tuberculosis Standards (2022)\(^6,7,10\)
<table>
<thead>
<tr>
<th>Intended users, target population</th>
<th>Intervention and practice considered</th>
<th>Major outcomes considered</th>
<th>Evidence collection, selection, and synthesis</th>
<th>Evidence quality assessment</th>
<th>Recommendations development and evaluation</th>
<th>Guideline validation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>low quality/ inconsistent results, or only 1 observational study available.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CRGC = Canadian Respiratory Guidelines Committee; GRADE = Grading of Recommendations, Assessment, Development and Evaluations; NR = not reported; RC = randomized-controlled trial; SR = systematic review; TB = tuberculosis; vs. = versus.

Note: This table has not been copy-edited.
### Table 3: Strengths and Limitations of Guideline Using AGREE II

<table>
<thead>
<tr>
<th>Item</th>
<th>Canadian Tuberculosis Standards (2022)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Domain 1: Scope and purpose</strong></td>
<td></td>
</tr>
<tr>
<td>1. The overall objective(s) of the guideline is (are) specifically described.</td>
<td>Yes</td>
</tr>
<tr>
<td>2. The health question(s) covered by the guideline is (are) specifically described.</td>
<td>No</td>
</tr>
<tr>
<td>3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 2: Stakeholder involvement</strong></td>
<td></td>
</tr>
<tr>
<td>4. The guideline development group includes individuals from all relevant professional groups.</td>
<td>Partially</td>
</tr>
<tr>
<td>5. The views and preferences of the target population (patients, public, etc.) have been sought.</td>
<td>No</td>
</tr>
<tr>
<td>6. The target users of the guideline are clearly defined.</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 3: Rigour of development</strong></td>
<td></td>
</tr>
<tr>
<td>7. Systematic methods were used to search for evidence.</td>
<td>No</td>
</tr>
<tr>
<td>8. The criteria for selecting the evidence are clearly described.</td>
<td>No</td>
</tr>
<tr>
<td>9. The strengths and limitations of the body of evidence are clearly described.</td>
<td>No</td>
</tr>
<tr>
<td>10. The methods for formulating the recommendations are clearly described.</td>
<td>Partially</td>
</tr>
<tr>
<td>11. The health benefits, side effects, and risks have been considered in formulating the recommendations.</td>
<td>Unclear</td>
</tr>
<tr>
<td>12. There is an explicit link between the recommendations and the supporting evidence.</td>
<td>No</td>
</tr>
<tr>
<td>13. The guideline has been externally reviewed by experts before its publication.</td>
<td>Yes</td>
</tr>
<tr>
<td>14. A procedure for updating the guideline is provided.</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 4: Clarity of presentation</strong></td>
<td></td>
</tr>
<tr>
<td>15. The recommendations are specific and unambiguous.</td>
<td>Yes</td>
</tr>
<tr>
<td>16. The different options for management of the condition or health issue are clearly presented.</td>
<td>NA</td>
</tr>
<tr>
<td>17. Key recommendations are easily identifiable.</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Domain 5: Applicability</strong></td>
<td></td>
</tr>
<tr>
<td>18. The guideline describes facilitators and barriers to its application.</td>
<td>No</td>
</tr>
<tr>
<td>19. The guideline provides advice and/or tools on how the recommendations can be put into practice.</td>
<td>No</td>
</tr>
<tr>
<td>20. The potential resource implications of applying the recommendations have been considered.</td>
<td>No</td>
</tr>
<tr>
<td>21. The guideline presents monitoring and/or auditing criteria.</td>
<td>No</td>
</tr>
<tr>
<td><strong>Domain 6: Editorial independence</strong></td>
<td></td>
</tr>
<tr>
<td>22. The views of the funding body have not influenced the content of the guideline.</td>
<td>Yes</td>
</tr>
<tr>
<td>23. Competing interests of guideline development group members have been recorded and addressed.</td>
<td>Yes</td>
</tr>
</tbody>
</table>

AGREE II = Appraisal of Guidelines for Research and Evaluation II.  
Note that this table has not been copy-edited.
### Appendix 4: Main Study Findings

**Table 4: Summary of Recommendations in Included Guideline**

<table>
<thead>
<tr>
<th>Recommendations and supporting evidence</th>
<th>Quality of evidence and strength of recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Canadian Tuberculosis Standards (2022)</strong>&lt;sup&gt;57&lt;/sup&gt;</td>
<td>NA</td>
</tr>
</tbody>
</table>

Note: No specific recommendations regarding delayed TST were provided in the guideline. General statements regarding delayed TST in high and medium priority contacts reported in the guideline are provided below.

- “If a TST is the screening test for LTBI, high-priority contacts should ideally have both an initial TST immediately and a second TST at least 8 weeks from the last day of exposure, to identify conversion. If LTBI screening is done by IGRA, a single test at 8 weeks after exposure should be done. (p.172)<sup>5</sup>
- In many medium-priority exposure settings, it is most practical to do a single round of screening after 8 weeks from the last exposure. (p.172)<sup>5</sup>
- “In the context of a contact investigation, to identify a true conversion (i.e., new infection), a single TST should be performed as soon as possible after an exposure to TB is recognized and the contact is identified. If the first TST is negative and performed less than 8 weeks after contact with the index patient, then a second TST should be scheduled no sooner than 8 weeks after the contact was broken. This also means for contacts that are identified more than 8 weeks after contact with an index patient is broken (e.g., casual contacts), a single TST will identify all those with new infection. (p.56)<sup>7</sup>

IGRA = interferon gamma release assay; LTBI = latent tuberculosis infection; NA = not applicable; TB = tuberculosis; TST = tuberculin skin testing.

Note that this table has not been copy-edited.
Appendix 5: References of Potential Interest

Previous CADTH Reports


Systematic Reviews


Economic Evaluations

Guidelines and Recommendations
Alternate Population


Additional References


